AllianceBernstein’s Aclaris Therapeutics ACRS Stock Holding History

AllianceBernstein’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Buy	57,000 +41,800	+275%	+$186K	﹤0.01%	3124
2026 Q1	$45.8K	Hold	15,200	–	–	﹤0.01%	3200
2025 Q4	$45.8K	Hold	15,200	–	–	﹤0.01%	3207
2025 Q3	$28.9K	Hold	15,200	–	–	﹤0.01%	3231
2025 Q2	$21.6K	Buy	+15,200	New	+$20.6K	﹤0.01%	3230
2024 Q2	–	Sell	-60,400	Closed	-$74.9K	–	3233
2024 Q1	$74.9K	Hold	60,400	–	–	﹤0.01%	3055
2023 Q4	$63.4K	Hold	60,400	–	–	﹤0.01%	3115
2023 Q3	$414K	Hold	60,400	–	–	﹤0.01%	2665
2023 Q2	$626K	Hold	60,400	–	–	﹤0.01%	2518
2023 Q1	$489K	Hold	60,400	–	–	﹤0.01%	2585
2022 Q4	$951K	Buy	60,400 +14,300	+31%	+$230K	﹤0.01%	2311
2022 Q3	$726K	Hold	46,100	–	–	﹤0.01%	2460
2022 Q2	$644K	Buy	46,100 +4,300	+10%	+$60.3K	﹤0.01%	2565
2022 Q1	$721K	Buy	41,800 +9,200	+28%	+$126K	﹤0.01%	2537
2021 Q4	$474K	Buy	32,600 +4,800	+17%	+$72.7K	﹤0.01%	2769
2021 Q3	$500K	Hold	27,800	–	–	﹤0.01%	2755
2021 Q2	$488K	Buy	+27,800	New	+$631K	﹤0.01%	2823
2020 Q2	–	Sell	-55,200	Closed	-$57K	–	3197
2020 Q1	$57K	Hold	55,200	–	–	﹤0.01%	3039
2019 Q4	$104K	Hold	55,200	–	–	﹤0.01%	3034
2019 Q3	$60K	Hold	55,200	–	–	﹤0.01%	3118
2019 Q2	$121K	Buy	55,200 +7,700	+16%	+$42K	﹤0.01%	3050
2019 Q1	$285K	Buy	47,500 +8,000	+20%	+$53K	﹤0.01%	2779
2018 Q4	$292K	Buy	39,500 +8,600	+28%	+$88.6K	﹤0.01%	2744
2018 Q3	$449K	Buy	30,900 +2,100	+7%	+$36K	﹤0.01%	2668
2018 Q2	$575K	Buy	28,800 +5,200	+22%	+$96.1K	﹤0.01%	2564
2018 Q1	$413K	Buy	23,600 +4,100	+21%	+$86.9K	﹤0.01%	2574
2017 Q4	$481K	Hold	19,500	–	–	﹤0.01%	2542
2017 Q3	$503K	Hold	19,500	–	–	﹤0.01%	2571
2017 Q2	$529K	Buy	19,500 +10,200	+110%	+$277K	﹤0.01%	2589
2017 Q1	$277K	Buy	9,300 +1,800	+24%	+$51.9K	﹤0.01%	2744
2016 Q4	$204K	Buy	+7,500	New	+$191K	﹤0.01%	2886

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

AllianceBernstein's ACRS Position: Q2 2026 in Review

AllianceBernstein increased its Aclaris Therapeutics (ACRS) stake by 275% in Q2 2026, buying an estimated $186K and bringing the position to 57,000 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #3124.

AllianceBernstein first reported a position in ACRS in Q4 2016 and has held it in 31 quarters since. The position peaked at $951K in Q4 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

AllianceBernstein held 57,000 shares of Aclaris Therapeutics worth $214K as of Q2 2026.
AllianceBernstein bought 41,800 Aclaris Therapeutics shares in Q2 2026, an estimated $186K.
Aclaris Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3124 holding.
AllianceBernstein first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 31 quarters since.
AllianceBernstein's Aclaris Therapeutics position peaked at $951K in Q4 2022.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.